Bolt Biotherapeutics (BOLT) has received a new Buy rating, initiated by H.C. Wainwright analyst, Robert Burns.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Robert Burns has given his Buy rating due to a combination of factors surrounding Bolt Biotherapeutics’ innovative approach in cancer treatment. The company’s lead asset, BDC-4182, is a Claudin 18.2-targeted immune-stimulating antibody conjugate that stands out from traditional antibody-drug conjugates by using an immune-stimulatory agent instead of a cytotoxic payload. This differentiation has shown promising preclinical results, demonstrating superior anti-tumor activity and a favorable safety profile in non-human primates.
Furthermore, Bolt Biotherapeutics is currently conducting a Phase 1 study for BDC-4182 in patients with advanced gastric and gastroesophageal cancer, with initial results expected in the third quarter of 2026. Despite a modest delay due to a strong immune response, the company is taking strategic steps to extend its financial runway into 2027, including a significant workforce reduction. Additionally, the recent reverse stock split has kept the company’s share price in compliance with NASDAQ requirements, and the discounted cash flow valuation supports a price target of $7 per share. However, potential risks such as data release delays and competitive pressures remain.